German prevention law welcome, but "could be better"
This article was originally published in Clinica
The German law on disease prevention, which reached its first reading in the German lower house (Bundestag) on February 18, has been generally welcomed by the country's diagnostics industry. But in virtually the same breath, the industry chides the government for missing an opportunity to make the law even more effective.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.